The journey of canakinumab; on- and off-label indications
The role of interleukin-1 (IL-1) has been studied in many diseases, ranging from auto-inflammatory diseases to malignancies, and much has been discovered. There are currently four IL-1 inhibitors available, but only two have been approved in Europe: the receptor antagonist anakinra, and the IL-1b se...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Verduci Editore
2019-05-01
|
| Series: | Beyond Rheumatology |
| Subjects: | |
| Online Access: | https://www.beyond-rheumatology.org/wp-content/uploads/sites/10/2022/05/br-1-1-4.pdf |
| _version_ | 1797831413860401152 |
|---|---|
| author | Daniela Marotto Alberto Batticciotto Angela Ceribelli Piercarlo Sarzi Puttini |
| author_facet | Daniela Marotto Alberto Batticciotto Angela Ceribelli Piercarlo Sarzi Puttini |
| author_sort | Daniela Marotto |
| collection | DOAJ |
| description | The role of interleukin-1 (IL-1) has been studied in many diseases, ranging from auto-inflammatory diseases to malignancies, and much has been discovered. There are currently four IL-1 inhibitors available, but only two have been approved in Europe: the receptor antagonist anakinra, and the IL-1b selective inhibitor canakinumab. The aim of this paper is to summarize the on- and off-label use of canakinumab (ILARIS). |
| first_indexed | 2024-04-09T13:51:40Z |
| format | Article |
| id | doaj.art-951a473dd760474cb6080f0ae55b28ed |
| institution | Directory Open Access Journal |
| issn | 2612-5110 |
| language | English |
| last_indexed | 2024-04-09T13:51:40Z |
| publishDate | 2019-05-01 |
| publisher | Verduci Editore |
| record_format | Article |
| series | Beyond Rheumatology |
| spelling | doaj.art-951a473dd760474cb6080f0ae55b28ed2023-05-08T14:41:23ZengVerduci EditoreBeyond Rheumatology2612-51102019-05-01110.4081/br.2019.4256The journey of canakinumab; on- and off-label indicationsDaniela Marotto0Alberto Batticciotto1Angela Ceribelli2Piercarlo Sarzi Puttini3P. Dettori Hospital, Tempio Pausania (SS), Internal Medicine Department, ASST Settelaghi, Ospedale di Circolo - Fondazione Macchi, Varese, ASST Fatebenefratelli-Sacco, Milano, Italy, ASST Fatebenefratelli-Sacco, Milano, Italy, The role of interleukin-1 (IL-1) has been studied in many diseases, ranging from auto-inflammatory diseases to malignancies, and much has been discovered. There are currently four IL-1 inhibitors available, but only two have been approved in Europe: the receptor antagonist anakinra, and the IL-1b selective inhibitor canakinumab. The aim of this paper is to summarize the on- and off-label use of canakinumab (ILARIS).https://www.beyond-rheumatology.org/wp-content/uploads/sites/10/2022/05/br-1-1-4.pdfil-1βinflammationinterleukin 1rheumatic diseaseil-1 inhibitorsauto-inflammatory diseasecapstrapsbiological therapiesfamilial mediterranean feveradult-onset still diseasesjiahidspregnancy |
| spellingShingle | Daniela Marotto Alberto Batticciotto Angela Ceribelli Piercarlo Sarzi Puttini The journey of canakinumab; on- and off-label indications Beyond Rheumatology il-1β inflammation interleukin 1 rheumatic disease il-1 inhibitors auto-inflammatory disease caps traps biological therapies familial mediterranean fever adult-onset still disease sjia hids pregnancy |
| title | The journey of canakinumab; on- and off-label indications |
| title_full | The journey of canakinumab; on- and off-label indications |
| title_fullStr | The journey of canakinumab; on- and off-label indications |
| title_full_unstemmed | The journey of canakinumab; on- and off-label indications |
| title_short | The journey of canakinumab; on- and off-label indications |
| title_sort | journey of canakinumab on and off label indications |
| topic | il-1β inflammation interleukin 1 rheumatic disease il-1 inhibitors auto-inflammatory disease caps traps biological therapies familial mediterranean fever adult-onset still disease sjia hids pregnancy |
| url | https://www.beyond-rheumatology.org/wp-content/uploads/sites/10/2022/05/br-1-1-4.pdf |
| work_keys_str_mv | AT danielamarotto thejourneyofcanakinumabonandofflabelindications AT albertobatticciotto thejourneyofcanakinumabonandofflabelindications AT angelaceribelli thejourneyofcanakinumabonandofflabelindications AT piercarlosarziputtini thejourneyofcanakinumabonandofflabelindications AT danielamarotto journeyofcanakinumabonandofflabelindications AT albertobatticciotto journeyofcanakinumabonandofflabelindications AT angelaceribelli journeyofcanakinumabonandofflabelindications AT piercarlosarziputtini journeyofcanakinumabonandofflabelindications |